Literature DB >> 26518253

Characterizing pain and associated coping strategies in methadone and buprenorphine-maintained patients.

Kelly E Dunn1, Patrick H Finan2, D Andrew Tompkins2, Michael Fingerhood3, Eric C Strain2.   

Abstract

BACKGROUND: Chronic pain is common among patients receiving opioid maintenance treatment (OMT) for opioid use disorder. To aid development of treatment recommendations for coexisting pain and opioid use disorder, it is necessary to characterize pain treatment needs and assess whether needs differ as a function of OMT medication.
METHODS: A point-prevalence survey assessing pain and engagement in coping strategies was administered to 179 methadone and buprenorphine-maintained patients.
RESULTS: Forty-two percent of participants were categorized as having chronic pain. Methadone patients had greater severity of pain relative to buprenorphine patients, though both groups reported high levels of interference with daily activities, and participants with pain attended the emergency room more frequently relative to participants without pain. Only 2 coping strategies were being utilized by more than 50% of participants (over-the-counter medication, prayer).
CONCLUSIONS: Results indicate that pain among OMT patients is common, severe, and of significant impairment. Methadone patients reported greater severity pain, particularly worse pain in the past 24h, though interference from pain in daily activities did not vary as a function of OMT. Most participants with pain were utilizing few evidenced-based pain coping strategies. Increasing OMT patient access to additional pain treatment strategies is an opportunity for immediate intervention, and similarities across OMT type suggest interventions do not need to be customized to methadone vs. buprenorphine patients.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Buprenorphine; Chronic pain; Coping; Methadone; Opioid

Mesh:

Substances:

Year:  2015        PMID: 26518253      PMCID: PMC4663104          DOI: 10.1016/j.drugalcdep.2015.10.018

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  37 in total

1.  Six- and ten-item indexes of psychological distress based on the Symptom Checklist-90.

Authors:  C S Rosen; K D Drescher; R H Moos; J W Finney; R T Murphy; F Gusman
Journal:  Assessment       Date:  2000-06

2.  Race, age, and back pain as factors in completion of residential substance abuse treatment by veterans.

Authors:  K Stack; J Cortina; C Samples; M Zapata; L F Arcand
Journal:  Psychiatr Serv       Date:  2000-09       Impact factor: 3.084

3.  The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations.

Authors:  Thomas M Atkinson; Tito R Mendoza; Laura Sit; Steven Passik; Howard I Scher; Charles Cleeland; Ethan Basch
Journal:  Pain Med       Date:  2010-01-15       Impact factor: 3.750

4.  Significantly higher methadone dose for methadone maintenance treatment (MMT) patients with chronic pain.

Authors:  Einat Peles; Shaul Schreiber; Jacob Gordon; Miriam Adelson
Journal:  Pain       Date:  2005-02       Impact factor: 6.961

5.  Treatment needs associated with pain in substance use disorder patients: implications for concurrent treatment.

Authors:  Jodie A Trafton; Elizabeth M Oliva; Doyanne A Horst; Jared D Minkel; Keith Humphreys
Journal:  Drug Alcohol Depend       Date:  2004-01-07       Impact factor: 4.492

6.  Providers' experiences treating chronic pain among opioid-dependent drug users.

Authors:  Karina M Berg; Julia H Arnsten; Galit Sacajiu; Alison Karasz
Journal:  J Gen Intern Med       Date:  2009-02-03       Impact factor: 5.128

7.  Allopathic, complementary, and alternative medical treatment utilization for pain among methadone-maintained patients.

Authors:  Declan T Barry; Mark Beitel; Christopher J Cutter; Brian Garnet; Dipa Joshi; Richard S Schottenfeld; Bruce J Rounsaville
Journal:  Am J Addict       Date:  2009 Sep-Oct

8.  Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities.

Authors:  Andrew Rosenblum; Herman Joseph; Chunki Fong; Steven Kipnis; Charles Cleland; Russell K Portenoy
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

9.  A comparison of characteristics and outcomes of opioid-dependent patients initiating office-based buprenorphine or methadone maintenance treatment.

Authors:  Michael I Fingerhood; Van L King; Robert K Brooner; Darius A Rastegar
Journal:  Subst Abus       Date:  2014       Impact factor: 3.716

10.  Validation of the Brief Pain Inventory for chronic nonmalignant pain.

Authors:  Gabriel Tan; Mark P Jensen; John I Thornby; Bilal F Shanti
Journal:  J Pain       Date:  2004-03       Impact factor: 5.820

View more
  14 in total

1.  A pilot study assessing acceptability and feasibility of hatha yoga for chronic pain in people receiving opioid agonist therapy for opioid use disorder.

Authors:  Lisa A Uebelacker; Donnell Van Noppen; Geoffrey Tremont; Genie Bailey; Ana Abrantes; Michael Stein
Journal:  J Subst Abuse Treat       Date:  2019-07-24

2.  Analgesic Effects of Hydromorphone versus Buprenorphine in Buprenorphine-maintained Individuals.

Authors:  Andrew S Huhn; Eric C Strain; George E Bigelow; Michael T Smith; Robert R Edwards; D Andrew Tompkins
Journal:  Anesthesiology       Date:  2019-01       Impact factor: 7.892

3.  Motivations to initiate injectable hydromorphone and diacetylmorphine treatment: A qualitative study of patient experiences in Vancouver, Canada.

Authors:  Samara Mayer; Al Fowler; Isabella Brohman; Nadia Fairbairn; Jade Boyd; Thomas Kerr; Ryan McNeil
Journal:  Int J Drug Policy       Date:  2020-09-16

Review 4.  A Neurobehavioral Approach to Addiction: Implications for the Opioid Epidemic and the Psychology of Addiction.

Authors:  Antoine Bechara; Kent C Berridge; Warren K Bickel; Jose A Morón; Sidney B Williams; Jeffrey S Stein
Journal:  Psychol Sci Public Interest       Date:  2019-10

5.  The Impact of Childhood Emotional Abuse on Pain Interference Among People with Chronic Pain who Inject Drugs in Vancouver, Canada.

Authors:  Amy Prangnell; Jean Shoveller; Pauline Voon; Hennady Shulha; Cameron Grant; M-J Milloy; Thomas Kerr; Kanna Hayashi
Journal:  Pain Med       Date:  2020-04-01       Impact factor: 3.750

6.  Chronic pain, craving, and illicit opioid use among patients receiving opioid agonist therapy.

Authors:  Judith I Tsui; Marlene C Lira; Debbie M Cheng; Michael R Winter; Daniel P Alford; Jane M Liebschutz; Robert R Edwards; Jeffrey H Samet
Journal:  Drug Alcohol Depend       Date:  2016-06-27       Impact factor: 4.492

7.  Chronic non-cancer pain among adults with substance use disorders: Prevalence, characteristics, and association with opioid overdose and healthcare utilization.

Authors:  William S John; Li-Tzy Wu
Journal:  Drug Alcohol Depend       Date:  2020-02-11       Impact factor: 4.492

8.  Reward Responsiveness in Patients with Opioid Use Disorder on Opioid Agonist Treatment: Role of Comorbid Chronic Pain.

Authors:  Patrick H Finan; Janelle Letzen; David H Epstein; Chung Jung Mun; Samuel Stull; William J Kowalczyk; Daniel Agage; Karran A Phillips; Diego A Pizzagalli; Kenzie L Preston
Journal:  Pain Med       Date:  2021-09-08       Impact factor: 3.750

9.  Psychiatric comorbidity and order of condition onset among patients seeking treatment for chronic pain and opioid use disorder.

Authors:  Declan T Barry; Mark Beitel; Christopher J Cutter; David A Fiellin; Lynn M Madden; Nathan Lipkind; Pooja Bollampally; Christopher Liong; Richard S Schottenfeld
Journal:  Drug Alcohol Depend       Date:  2021-02-15       Impact factor: 4.492

10.  A Pilot Investigation of Nonpharmacological Pain Management Intervention Groups in Methadone Maintenance Treatment.

Authors:  Kimberly A DiMeola; Jeff Haynes; Meredith Barone; Mark Beitel; Lynn M Madden; Christopher J Cutter; Anthony Raso; Marina Gaeta; Xiaoying Zheng; Declan T Barry
Journal:  J Addict Med       Date:  2022 Mar-Apr 01       Impact factor: 3.702

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.